20
Participants
Start Date
October 25, 2021
Primary Completion Date
June 30, 2026
Study Completion Date
June 30, 2026
VAL-413
a flavored preparation of orally administered irinotecan
Temozolomide
alkylating oral chemotherapy agent used to treatment brain cancers
RECRUITING
Children's National Research Institute - Children's National Hospital, Washington D.C.
RECRUITING
University of North Carolina at Chapel Hill - North Carolina Cancer Hospital, Chapel Hill
RECRUITING
Duke University Children's Hospital and Health Center, Durham
RECRUITING
Atrium Health Levine Children's Hospital - Carolinas Medical Center, Charlotte
RECRUITING
Sarah Cannon Research Institute, Pediatric Hematology & Oncology, Nashville
RECRUITING
Indiana University School of Medicine, Riley Hospital for Children, Indianapolis
RECRUITING
UCSF, Mission Bay - Benioff Children's Hospital, San Francisco
RECRUITING
Cincinnati Children's Hospital Medical Center, Cincinnati
Valent Technologies, LLC
INDUSTRY